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Implication for health policy/practice/research/medical education:
Metformin, with the chemical name of 1,1-dimethylbiguanide hydrochloride, is in the first line of treatment of patients with type 
2 diabetes. Metformin treatment reduced inflammatory markers such as IL-1β, iNOS, and TNF-α, and reduced the number of 
microglia cells, and accordingly, it inhibited the inflammatory response. It was indicated that metformin reduced levels of ROS 
and NO and increased the antioxidant system, such as SOD.
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Metformin is one of the oldest and commonly used blood sugar lowering drugs, having limited 
side effects and used as the first line treatment in patients suffering from diabetes mellitus. 
Moreover, various studies have emphasized on the anti-inflammatory and antioxidant role 
of metformin, with multiple mechanisms, which activation of AMPK by metformin has 
had a key role in many of them. During the searches on the internet websites of PubMed, 
Elsevier, Google Scholar, and Science Direct, 76 papers related to the anti-inflammatory and 
antioxidant role of metformin were selected and reviewed since 2003 to 2017. At the cellular 
level, metformin suppresses the inflammation in many cases and reduces or eliminates 
inflammatory factors mainly through dependent mechanisms and sometimes independent of 
AMPK at the cellular level and through other ways at the systematic levels. It is also effective 
in reducing the level of oxidative stress factors by regulating the antioxidant system of the cell. 
All evidence suggests the antioxidant and anti-inflammatory role of metformin in various 
conditions. Metformin can be an appropriate treatment option for many diseases, which 
inflammatory processes and oxidative stress play a role in their pathogenesis.
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Metformin, with chemical name of 1,1-dimethylbiguanide 
hydrochloride, is in the first line of treatment of patients 
with type 2 diabetes. Side effects of this drug are limited. 
The most important of them is increasing the blood lactate 
levels, its use has been limited in people with chronic 
kidney disease (CKH), liver and heart failure (HF) (1). 
It seems that metformin to be effective in reducing the 
production of glucose from liver cells (gluconeogenesis), 
reducing insulin resistance, reducing fasting plasma 
insulin level, and activating the absorption of peripheral 
blood glucose by adenosine monophosphate-activated 
protein kinase (AMPK) (2-5). AMPK is an important 
factor in regulating the energy balance and its activation 
is associated with increasing the ratio of AMP to ATP. 
This enzyme plays various roles in different diseases (6,7). 
Clinical studies have proven the protective effect of this 
drug in various tissues, including reduced stroke and 
thrombotic risk factors, death caused by cardiovascular 
diseases, endothelial cell inflammation, the proliferation of 
aorta smooth muscle cells, and anti-teratogenic property 
(2-4). Additionally, various studies have revealed the 
role of metformin in anti-inflammatory, anti-apoptotic, 
and antioxidant processes (8-10). Various studies have 
proposed different mechanisms for anti-inflammatory 
and antioxidant role of metformin, such as increasing the 
insulin level, followed by suppressing the inflammatory 
processes through decreasing blood glucose and regulating 
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the molecules involved in inflammation (11,12).
Materials and Methods
For this review, we used a variety of sources including 
PubMed, Embase, Scopus and directory of open access 
journals (DOAJ). The search was conducted by using 
combinations of the following key words and or their 
equivalents; metformin, oxidative stress, inflammation, 
AMPK.
Anti-inflammatory role of metformin
Metformin and pre-inflammatory transcription factors
The nuclear factor kappa B (NF-ⱪB) is a transcription 
regulator involved in inflammation. By regulating the 
signaling, this factor can disrupt the process of several 
inflammatory pathways, cell death, and tissue destruction 
(13). In an examination conducted on mice with traumatic 
spinal cord injury, it was revealed that complex reactions 
of local inflammation along with microglia proliferation 
and activation, infiltration of phagocyte and increased 
production of pre-inflammatory cytokines occur in such 
conditions (14). Metformin can restrict the neuronal 
damage and disabilities caused by it during the early 
days through applying its anti-inflammatory effect by 
reducing the expression of NF-kB (2,7). By reducing the 
phosphorylation of signal transducer and activator of 
transcription (STAT) through increasing the activation 
of AMPK, metformin inhibits the differentiation of 
monocyte into macrophages (15). In a research conducted 
in 2006, it was shown that metformin inhibited the 
expression of NF-kB-dependent genes, such as pre-
inflammatory molecules and adhesion molecules such 
as intercellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1(VCAM-1), selectin E, and 
monocyte chemoattractant protein-1 (MCP-1) (7). It has 
been shown that metformin inhibits the production of 
IL-8 and IL-1α inflammatory cytokines significantly by 
inhibiting the activation of NF-kB and phosphorylation of 
inhibitor of kappa B (IkB) in the intestinal epithelial cells 
of mice with acute colitis (16). Metformin also suppresses 
the expression of CXCL8 induced by lipopolysaccharide 
(LPS) by inhibiting NF-kB. This cytokine contributes in 
changing the microenvironment around the tumor by 
calling leukocytes and endothelial progenitors involved in 
angiogenesis (17).
In a research conducted to evaluate the anti-fibrotic 
effects of metformin in heart muscle cells, it was revealed 
that aldosterone can increase the expression of pro-
inflammatory mediators of the TRAF3 interacting protein 
(TRAF3IP2) signaling pathway and the production of 
inflammatory cytokines such as IL-6, IL-17 and IL-18 
through inducing oxidative stress (5,18,19). TRAF3IP2 is 
a cytoplasmic adapter molecule responding to oxidative 
stress, which induces production of several transcription 
factors such as NF-ⱪB, AP-1, and C/EBPβ, and it is 
involved in the expression of inflammatory mediators. 
Investigations have indicated that metformin can inhibit 
the TRAF3IP2 molecule activated by aldosterone through 
activating the AMPK. It is also able to target the NF-ⱪB or 
C/EBPβ transcription factors activation pathway, leading 
to reduced or stopped production of the inflammatory 
cytokines. Finally, proliferation and migration of cardiac 
fibroblasts are reduced and the risk of cardiac fibrosis 
is moderated (5,20-22). Metformin applies its anti-
inflammatory effect in atherosclerosis by inhibiting the 
phosphorylation of transcription factors P38, JNK and 
AKT induced by IL-1 in smooth muscle cells. It also reduces 
the production of IL-6 and IL-8 (cytokines responsible for 
calling monocytes and adhesion of epithelial cells) from 
epithelial cells and macrophages (23).
Metformin and inflammatory markers
Various studies have indicated different impacts of 
metformin on C-reactive protein (CRP) (24-26). CRP 
is one of the most important inflammatory markers 
and plays an important role in the pathogenesis of 
cardiovascular diseases, obesity, insulin resistance 
syndrome and polycystic ovary. In a study conducted with 
large sample size, metformin reduced CRP level after 24 
weeks, but the mechanism of its action was not accurately 
determined (4,27). In a meta-analysis carried out on 
20 studies involving 433 women with polycystic ovary 
syndrome, the decreasing effect of metformin on CRP 
plasma levels, especially in obese women, was confirmed 
(28). In another meta-analysis conducted on 216 studies, 
it was found that metformin significantly reduced CRP 
in women with polycystic ovary syndrome, but it did not 
significantly affect the IL-6 (29).
Tumor necrosis factor-alpha (TNF-α) is an important 
inflammatory cytokine, produced as a result of bacterial 
and viral infections in the body and can cause tissue 
damage and fibrosis (30). Cyclooxygenase-2 (COX-2) is 
also an essential protein involved in the production of 
prostaglandin during acute and chronic inflammation 
(31). In an investigation on the anti-inflammatory effects 
of metformin on inflammation caused by LPS in human 
middle ear epithelial cell lines (HMEECs), it was shown 
that the effect of LPS increases the levels of TNF-α and 
COX-2. By assessing the values of these factors with real-
time polymerase chain reaction (PCR) and western blot 
method, they realized that pre-treatment with metformin 
could suppress the production of these inflammatory 
factors (30). In experimental arthritis, dose-dependent 
metformin could reduce the production and secretion of 
TNF-α and IL-6 and moderate the inflammation through 
AMPK activation (32). Likewise, in another research, it was 
revealed that metformin could reduce the concentration 
of inflammatory marker YKL-40 (33). Metformin also 
reduces the production of sepsis inflammatory cytokines, 
produced by neutrophils and monocytes, including IL-
6, IL-1β, and TNF-α (34). In an investigation on obese 
children aged 6 to 12 years, it was found that metformin 
reduced the level of inflammatory factors such as 
TNF-α, IL-8 and insulin resistance (35). In the ischemic-
reperfusion model, it was shown that metformin reduced 
the expression of induced pre-inflammatory factors such 
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as TNF-α, IL-1β, TLR4 and Ccr2, and the penetration of 
monocytes and macrophages (36).
The process of obesity is associated with increased oxidative 
and pro-inflammatory factors. Migratory inhibitor factor 
(MIF) is one of the most important inflammatory factors, 
secreted from adipose tissue and cells such as macrophage 
and monocyte. It can be involved in forming the sclerotic 
plaques. Its value is also increased in people with type 2 
diabetes and it is an essential mediator for initiating the 
acquired immune responses. An investigation conducted 
in 2004 revealed that the effect of metformin on obese 
people significantly reduced the expression of mRNA 
and secretion of MIF, and the anti-inflammatory role of 
metformin and its effect on reducing the atherosclerotic 
processes were observed (37). 
Advanced glycation end products (AGEs) are one of 
the most important inflammatory factors in diabetes, 
affecting the atherosclerosis development. With an 
effect on macrophages, these factors exacerbate the 
expression of pro-inflammatory cytokines (IL-1, IL-6 
and TNF-α), increase the RAGE expression, and activate 
NF-βB pathway. In fact, RAGE/NF-kB signaling plays 
role in the inflammatory activity of AGE-stimulated 
macrophages (38). Activating the AMPK and inhibiting 
the NF-ⱪB, metformin suppresses the pathway of RAGE/
NF-kB, leading to inhibited effects of AGE and change 
of phenotype of macrophages from M1 (classical or 
inflammatory) to M2 (alternatives) by changing the 
expression of their surface markers (CD86 and CD206, 
respectively). Finally, the production of inflammatory 
cytokines and inhibitory cytokines (IL-10) would 
increase (39). By producing the high mobility group box 
1 (HMGB1), which has pseudo-cytokine activity, necrotic 
cells are able to stimulate many receptors, including 
TLR4 and RAGE and induce inflammatory responses. 
Metformin can be attached directly to the extracellular 
HMGB1 on C-terminal sequence and inhibit it (40).
Inflammation plays a crucial role in the death of 
dopaminergic neurons and development of Parkinson 
disease as a result (3). The change in ATP mitochondrial 
production in this disease can damage the neurons and 
production of danger-associated molecular patterns 
(DAMP). Identifying the DAMPs by microglia would 
result in initiating the inflammatory and neurotoxic 
activities (41). Metformin can pass through the blood-
brain barrier and affect the central nervous system. Recent 
studies confirmed the reducing role of metformin on the 
activity of microglia cells (42,43). Metformin injection 
in the Parkinson’s animal model reduced inflammatory 
markers such as IL-1β, iNOS, and TNF-α, and reduced the 
number of microglia cells, and accordingly, it inhibited the 
inflammatory response (44). However, metformin is not 
able to reduce the death of neuronal cells (3).
Metformin and regulation of cell differentiation
Multiple sclerosis (MS) is one of the autoimmune 
inflammatory diseases, which its accurate mechanism 
of action has not been fully understood. Investigations 
suggest that TH17 cells response against myelin nerves 
and dysfunction of Treg cells are very effective in its 
pathogenesis. In the EAE mouse model of this disease, 
the accumulation of TH17 cells was seen in the central 
nervous system. They are involved in pathogenesis of this 
disease by the production of IL-17 followed by inducing 
the production of other pre-inflammatory cytokines 
such as IL-1 and IL-6 (45). In a research conducted in 
2016 to investigate the role of metformin in regulating 
the TH17/Treg balance in the EAE mouse model and 
several other studies, it was shown that injecting the 
metformin can improve the clinical signs of EAE. 
These studies revealed that metformin suppressed the 
expression of mammalian target of rapamycin (mTOR) 
and STAT3 transcription factors and the factors regulating 
differentiation and activation of TH17 cells by activating 
AMPK, and thereby, it prevented the proliferation and 
penetration of these cells into central nervous system 
(CNS). In addition, by activating AMPK, metformin can 
increase the proliferation of Treg cells and increase their 
infiltration to the central nervous tissue, and induce the 
production of anti-inflammatory cytokines such as IL-
10 and TGF-β from these cells, and thereby, it changes 
the balance of TH17/Treg by more production of Treg 
and reduction of TH17 (45,46). Another mechanism 
involved in regulating this cellular balance by metformin 
is its effect on metabolic pathways. Th17 cells, compared 
to Treg, require more energy to apply its effect and they 
obtain their energy through pathways such as aerobic 
glycolysis and glutamine catabolism. Signaling mTOR 
and its downstream genes are involved in inducing these 
metabolic pathways, while Treg cells obtain their energy 
through lipid oxidation (47,48). By increasing the activation 
of AMPK in the liver cells, followed by mTOR inhibition, 
metformin causes induction of the genes involved in lipid 
metabolism, reduced glycolysis and glutamine catabolism, 
and thereby, it reduces the TH17 cells and reduces the 
inflammation (49). In an investigation conducted in 2016 
on intraperitoneal injection of metformin in patients with 
acute graft-versus-host disease (αGVHD), it was shown 
that the activation of AMPK signaling reduces the severity 
of this reaction. Due to the effect of metformin, STAT3 
activity is reduced, mTOR/STAT3 signaling is inhibited, 
leading to induction of autonomy, and it changes the 
TH17/Treg cellular balance toward more production 
of Treg cells (50). In addition, in the SLE mouse model, 
oral injection of metformin inhibited the differentiation 
of B cells from plasmas cells and changed the process of 
production of autoantibody, inhibited the formation of 
germ cells, and penetration of inflammatory cells into 
tissues such as the liver and kidney, by regulating the 
AMPK-mTOR-STAT3 signaling pathway. These changes 
were associated with inhibiting the differentiation of T 
cells into inflammatory subgroups such as TH17 and TFH 
and increasing the differentiation to Treg (51).
The antioxidant role of metformin
Hyperglycemia induces the oxidative stress. An 
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investigation conducted on 208 patients with diabetes 
mellitus suggests increased oxidative stress markers 
such as advanced oxidation protein product (AOPP), 
pentosidine, and reactive oxygen species (ROS) in 
these people. In addition, the level of nitric oxide, as an 
important mediator in nerve, immune and cardiovascular 
systems, decreased. After injecting the metformin in these 
people, level of oxidative stress indices decreased and the 
nitric oxide levels significantly increased (52).
ROS are produced in the mitochondrial electron transfer 
chain and cause production of ATP from ATP synthase. 
During these inflammatory processes, such as bacterial 
infection and stimulation with LPS, the production 
of these oxidants increases. Studies have revealed that 
administration of metformin stops the production of 
free oxygen radicals by direct inhibiting of the complex 
I electron transfer complex chain (NADH ubiquitin 
oxidoreductase (NADH) (30,53). 
Inhibition of complex I chain reduces the production of 
ATP and increases the ratio of ADP/ATP and AMP/ATP, 
which is the main stimulant for activation of the AMPK. 
This complex is involved in inducing the production 
of IL-1β through ROS. By blocking the complex I, 
metformin inhibited the production of IL-1β induced by 
LPS and increased the production of IL-10 (54). It was 
also revealed that metformin can apply its antioxidant 
effects by inhibiting NAD (P)H/PKC oxidase pathways 
(55). In an investigation conducted to evaluate the 
antioxidant role of metformin in the oxidative damage 
induced mouse model in the liver by carbon tetrachloride, 
it was found that the level of liver aminotransferases was 
reduced and its histopathological characteristics were 
improved following treatment with metformin. The 
dose-dependent metformin also reduced the level of liver 
peroxide hydrogen (56). 
Stimulating the mineralocorticoid receptors and NOX4, 
aldosterone increases the production of H2O2 in cardiac 
fibroblasts, followed by inducing the expression of the 
cytoplasmic adapter TRAF3IP2. In these conditions, 
metformin inhibits oxidative reactions by applying its 
antioxidant effects. Metformin can play its role through 
several different mechanisms, including 1) direct trapping 
of hydroxyl radicals; 2) activating antioxidant enzymes 
such as catalase, which is the main decomposer of H2O2; 
and 3) reducing the transcription from NOX4 in long-
term injection of metformin (5,57,58). 
TGF-β is one of the most important inflammatory factors, 
stimulating the production of ROS, accumulation of 
inflammatory cells in the lung, pulmonary fibrosis in 
mice with asthma by activating the Sma mothers against 
decapentaplegic (SMAD2/3) and mitogen-activated 
protein kinase (MAPK) signaling pathways (59,60). 
Activating the AMPK and inhibiting the TGF-β signaling 
and inducing endogen antioxidant system including 
glutathione  reductase (GSH), superoxide dismutase 
(SOD) and catalase (CAT), metformin reduces the ROS 
and malondialdehyde (61-63). In a research conducted 
by Hyun et al on an animal model of peritoneal dialysis, 
it was shown that by independent and dependent AMPK 
mechanisms, metformin can reduce ROS production, 
inhibit NADPH oxidase (NOX) activation, and 
exacerbate antioxidant activity and SOD expression in 
mesothelial cells (64). In addition, metformin activated 
the transcription factor of SKN-1/Nrf2 and increased the 
expression of antioxidant genes in animal models (65).
In the process of sepsis pathogenesis, the abundant 
production of inflammatory cytokines leads to increased 
production of cytokines and ROS by leaving an effect on 
microglia and endothelial cells. This oxidative stress can be 
involved in the onset of brain damages. Investigations have 
indicated that metformin leads to AKT phosphorylation 
by phosphatidylinositol-3-kinase (PI3K) activation, which 
this process is involved in maintaining mitochondrial 
integrity and increasing the ability to cope with damage 
induced by inflammation and oxidative stress. By 
inducing the production and increasing the activity of the 
antioxidant system, such as SOD, metformin cleans the 
ROS from brain tissue (34,66,67).
During the brain ischemia, ROS production increases 
in tissue. In these conditions, the value of antioxidant 
nuclear factor erythroid 2-related factor (Nrf2), which is 
an oxidative stress sensor, and hexokinase increase in the 
hippocampus, and then, decrease in time-dependent form. 
In addition, AMP and ATP levels increase and decrease, 
respectively, under ischemia and it acts as a stimulant 
for AMPK activity. AMPK is able to stabilize Nrf2 and 
induce its gene expression. The induction of the Nrf2 
pathway is associated with increasing level of antioxidant 
system enzymes of body such as CAT, GSH and SOD. In 
this regard, by induction of AMPK activation, metformin 
stimulates the onset of this pathway and applies its 
antioxidant role (44).
Various studies have emphasized the major role of oxidative 
stress and consequently increase in the indicators resulting 
from the oxidation of lipids and proteins in the early phase 
of Alzheimer’s disease. In an investigation conducted by 
Chen and Zhong on Alzheimer disease, it was shown that 
the oxidation of proteins was associated with reduced 
glucose metabolism in brain cells, followed by disorder 
in glucose humoral and neuronal dysfunction (68,69). 
Moreover, increasing the reactive nitrogen species (RNS) 
in animal models might cause beta-amyloid deposition in 
the brain tissue, which might lead into electron transfer 
chain disruption, mitochondrial dysfunction, and 
increased ROS production (70). The AMPK activation by 
metformin induces autophagy and decomposes the beta-
amyloid and improves the neurological changes related to 
Alzheimer’s disease (71).
In an investigation conducted in 2016, it was indicated 
that metformin reduced levels of ROS and NO in mouse 
adipose-derived stem cells (MuASCs) and increased the 
antioxidant system, such as SOD (72). By reducing the 
level of ROS and MDA and increasing the production 
and activity of GSH, metformin also can inhibit the 
oxidative stress associated with arsenic and butyric acid 
(73). In another study, it was revealed that oxidative stress 
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markers were reduced in the culture of mouse olfactory 
ensheathing cells (mOECs), which received metformin 
(74). Algire et al indicated that metformin, independent 
of AMPK, reduced the production of ROS resulting from 
the effect of paraquat and prevented DNA damage and 
mutation (75). In another investigation on the stroke 
experimental model, metformin injection reduced the 
level of ROS by regulating antioxidant activity (76).
Conclusion 
Numerous experimental studies have been conducted to 
evaluate the role of metformin in inhibiting inflammatory 
processes and oxidative stress, but limited clinical studies 
have been conducted in this regard. It has shown different 
effects in vitro and in vivo conditions. Moreover, the 
mechanism of action of this drug has been different 
under various conditions. By examining the process of 
inflammatory and oxidative diseases and metformin role 
in controlling or changing these pathways in clinical and 
laboratory conditions, we hope that this drug with fewer 
side effects to be used in the treatment of many diseases.
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